These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 7796281)

  • 1. Gene therapy approaches in urologic oncology.
    Vieweg J; Gilboa E
    Surg Oncol Clin N Am; 1995 Apr; 4(2):203-18. PubMed ID: 7796281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
    Loskog A; Tötterman TH; Böhle A; Brandau S
    Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines.
    Jaffee EM; Pardoll DM
    Methods; 1997 Jun; 12(2):143-53. PubMed ID: 9184378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor inhibitory factors in urologic malignancies].
    Uemura H
    Hinyokika Kiyo; 2008 Jan; 54(1):49-52. PubMed ID: 18260361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.
    Vieweg J; Rosenthal FM; Bannerji R; Heston WD; Fair WR; Gansbacher B; Gilboa E
    Cancer Res; 1994 Apr; 54(7):1760-5. PubMed ID: 8137291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular research in cancer: future clinical applications.
    Ratliff TL
    Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy of cancer with genetically modified tumor vaccines.
    Gilboa E
    Semin Oncol; 1996 Feb; 23(1):101-7. PubMed ID: 8607020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine and gene therapy of renal cell carcinoma.
    Gitlitz BJ; Belldegrun AS; Figlin RA
    Semin Urol Oncol; 2001 May; 19(2):141-7. PubMed ID: 11354534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy using cells modified with cytokine genes.
    Kowalczyk DW; Wysocki PJ; Mackiewicz A
    Acta Biochim Pol; 2003; 50(3):613-24. PubMed ID: 14515144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological principles and clinical development of prostate cancer gene therapy.
    Sanda MG
    Semin Urol Oncol; 1997 Feb; 15(1):43-55. PubMed ID: 9050139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cytokine gene transfer into tumors on host cell infiltration and regression.
    McBride WH; Economou JS; Syljuåsen RG; Parrish C; Hackman D; Latham V; Chiang CS; Dougherty GJ
    Anticancer Res; 1996; 16(3A):1139-43. PubMed ID: 8702225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine gene therapy: a new strategy for the management of cancer patients.
    Foa R; Guarini A; Cignetti A; Cronin K; Rosenthal F; Gansbacher B
    Nat Immun; 1994; 13(2-3):65-75. PubMed ID: 8173237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of cancer using cytokine gene-modified tumor vaccines.
    Gilboa E; Lyerly HK; Vieweg J; Saito S
    Semin Cancer Biol; 1994 Dec; 5(6):409-17. PubMed ID: 7703440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for CD40-directed experimental therapy of human cancer.
    Tong AW; Stone MJ
    Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.